Dr. Mary Garland Kledzik, MD

Dr. Kledzik practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Kledzik's NPI, 1083053888, was assigned on June 14, 2013. Dr. Kledzik holds West Virginia license 29755.

Dr. Kledzik's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Kledzik's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Kledzik is also affiliated with J.W. Ruby Memorial Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Kledzik to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kledzik practices, 5 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. Kledzik's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dr. Kledzik is licensed in West Virginia.

CMS data shows 104 Medicare services from Dr. Kledzik across 5 procedure codes in 2024, for 79 Medicare patients. Medicare paid $8,097 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 79 Medicare patients who saw Dr. Kledzik in 2024. The largest group is 75 to 84, with 38 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 1.92, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kledzik's median patient age at 65, with 48% women.

In 2024, Dr. Kledzik wrote 34 Medicare Part D claims for 25 patients. 100% of them were for generic drugs. CMS names the drug for 13 of them, across 1 drug with 11 or more claims each, at $166 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kledzik for performance year 2024, reported through an alternative payment model (APM). Dr. Kledzik accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kledzik as offering telehealth. CMS counts 21 procedures of melanoma (skin cancer) excision by Dr. Kledzik, more than 75% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

CMS Open Payments shows 4 general payments to Dr. Kledzik from 1 drug or device company from 2020 to 2025. Food and beverage make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $342.